Reporting TP53 gene analysis results in CLL
|
|
- Bernadette Parrish
- 5 years ago
- Views:
Transcription
1 Reporting TP53 gene analysis results in CLL
2 Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review 2017
3 Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity NCBI - TP53 and CLL
4 Mutations in TP53 - From discovery to clinical practice in CLL (cont d) Discovery Validation Clinical practice Variant diversity NCBI - TP53 and CLL Eichhorst (ESMO) Ann. Clin. Onc 2015 Stilgenbauer et al, Blood 2014 Gonzales JCO 2010 Rossi Clin Canc Res 2009 Dicker et al. Leukemia 2009 Zenz et al. Blood 2008 Malcikova et al. Mol. Immunol
5 Mutations in TP53 - From discovery to clinical practice in CLL (cont d) Discovery Validation Clinical practice Variant diversity Variant reports
6 From variant detection to clinical report Sequencing Detection
7 From variant detection to clinical report Sequencing Detection Validation Variant artifact Sanger: Enzyme Slippage Dye Blob DNA loop/hairpin Contamination NGS: PCR dublicates First bp read Low Q30/ Low Coverage Contamination
8 From variant detection to clinical report Sequencing Detection Validation Variant artifact VAF<10% omit variants with VAF <10% / not confirmable via Sanger 1) Higher risk for false positive results 2) Clinical significance remains unclear
9 From variant detection to clinical report Sequencing Detection Validation Variant Interpretation pathogenic variant artifact VAF<10% SNPs Single nucleotide polymorphisms or just polymorphisms are variants with a frequency of >1% in healthy. 97 known in TP53, only 5 exonic missense TP53 SNPs. Rest is rare non-disease coding variants or rare non-pathogenic variants.
10 From variant detection to clinical report Sequencing Detection Validation Variant Interpretation pathogenic variant artifact VAF<10% SNPs pathogenic or not? => Samesense, missense, intronic, exonic, splice site... => Databases (dbsnp, 1000g, IARC, COSMIC, SESHAT) => Prediction tools (SIFT, POLYPHEN) => Non-tumor control (CD19neg, saliva, remission sample)
11 From variant detection to clinical report Sequencing Detection Validation Variant Interpretation pathogenic variant hereditary pathogenic variants tumor associated pathogenic variant Report artfact VAF<10% SNPs pathogenic or not? => Samesense, missense, intronic, exonic, splice site... => Databases (dbsnp, 1000g, IARC, COSMIC, SESHAT) => Prediction tools (SIFT, POLYPHEN) => Non-tumor control (CD19neg, saliva, remission sample)
12 From variant detection to clinical report Sequencing Detection Validation Variant Interpretation pathogenic variant hereditary pathogenic variants tumor associated pathogenic variant Report Clinical consequence artifact VAF<10% SNPs pathogenic or not? => Samesense, missense, intronic, exonic, splice site... => Databases (dbsnp, 1000g, IARC, COSMIC, SESHAT) => Prediction tools (SIFT, POLYPHEN) => Non-tumor control (CD19neg, saliva, remission sample)
13 Evidence based variant categorization Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology and College of American Pathologists Li et al., Journal of Molecular Diagnostics 2016
14 Evidence based variant categorization What the clinician wants to know: Mutated or not? Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology and College of American Pathologists Li et al., Journal of Molecular Diagnostics 2016
15 Evidence based variant categorization What the clinician wants to know: Mutated or not? Mutation rare in TP53 SNP/ rare non pathogenic variant Li et al., Journal of Molecular Diagnostics 2016
16 TP53 mutation type Missense, Silent, Nonsense? ~ 73% of mutations are missense and the pathogenic value unclear (database!) ~17% of mutations are nonsense or frameshift=> generally pathogenic (database!). ~2% are splice site => pathogenic Silent and intronic mutations are generally of no pathogenic effect. However very few variants have proven effect on splicing and RNA processing (Database!)
17 TP53 mutation type (cont d) Exonic, intronic, splice site? TP53 exon 6
18 Intronic Splice site Splice site Intronic TP53 mutation type (cont d) Exonic, intronic, splice site? TP53 exon 6 Exonic
19 Intronic Splice site Splice site Intronic TP53 mutation type splice site mutations Exonic, intronic, splice site? TP53 exon 6 Exonic +/-2bp from start/end covers the splice site often characterized by AGGT
20 ERIC TP53 certification splice site mutations (cont d) Passed Good laboratory practice; 4 25 labs Failed All mutations detected, but exons 4-9 not covered; 1 Passed; 10 Wrong annotation; 1 Splice site mutation detected, but not evaluated as a mutation; 3 Splice site mutation not detected; 3 Not identified at least 2 samples correctly; 3
21 TP53 mutation analysis pitfalls in variant identification Missense, Silent, Nonsense? This nonsense mutation / stop codon leads to an amino acid substitution. p. R213R: The TP53 variant c.639a>g, which lead to an amino acid change in codon 213.
22 TP53 mutation analysis databases Population databases: 1000 Genomes Project, Exome Variant Server, dbsnp P72R SNP / Polymorphism
23 TP53 mutation analysis databases (cont d) Population databases: 1000 Genomes Project, Exome Variant Server, dbsnp??? P72R SNP / Polymorphism
24 TP53 mutation analysis databases (cont d) Cancer-specific variant databases Catalog of Somatic Mutations in Cancer (COSMIC) IARC TP53 mutation database
25 TP53 mutation analysis databases (cont d) Cancer-specific variant databases Catalog of Somatic Mutations in Cancer (COSMIC) IARC TP53 mutation database
26 % of Respondents TP53 mutation analysis pitfalls in variant identification What database do you use for mutation validation? Polymorphisms and Mutations ,83 61,02 52,54 40,68 27,12 Database 0 5,08. P72R: This SNP is likely benign, possible clinical significance affecting drug response. p.pro72arg (rs ) is related with a higher risk of breast cancer, and is not associated with Systemic Lupus Erythematosus in Caucasians, African-Americans, and Asian children and adult. IARC TP53 database TP53 website (UMD database COSMIC dbsnp ClinVar None I am not sure
27 TP53 mutation analysis pitfalls in variant identification Prediction tools SIFT prediction is based on the degree of conservation of amino acid residues in sequence alignments derived from closely related sequences Polyphen-2 possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations Specificity of only 60-80% i.e. SIFT result for BRAF V600E => Benign
28 TP53 mutation analysis pitfalls in variant identification Prediction tools SIFT prediction is based on the degree of conservation of amino acid residues in sequence alignments derived from closely related sequences Polyphen-2 possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations Specificity of only 60-80% i.e. SIFT result for BRAF V600E => Benign TA class Overall transcriptional activity (TA) on 8 different promoters Missense mutations are classified as "non-functional" if the median of promotor activity is <=20, "partially functional" if the median is >20 and <=75, "functional" if the median is >75 and <=140, and "supertrans" if the median is >140.
29 TP53 mutation analysis databases (cont d) Cancer-specific variant databases Catalog of Somatic Mutations in Cancer (COSMIC) IARC TP53 mutation database
30 TP53 mutation analysis non-tumor control Non-tumor control derived from tumor free material (saliva, buccal swap, bone marrow) or enriched / purified from same sample (purity control recommended) or sample from a time point of no measurable disease.
31 TP53 mutation analysis non-tumor control Non-tumor control derived from tumor free material (saliva, buccal swap, bone marrow) or enriched / purified from same sample (purity control recommended) or sample from a time point of no measurable disease. variant identified in tumor variant identified in control variant not identified in control rare non-pathogeneic variants germline mutation (very rare) somatic mutation Pitfalls: tumor contamination of nontumor material haematopoetic progenitor cells not considered
32 Should I look for germline variants? Non-tumor control derived from tumor free material (saliva, buccal swap, bone marrow) or enriched / purified from same sample (purity control recommended) or sample from a time point of no measurable disease. variant identified in tumor variant identified in control variant not identified in control rare non-pathogenic variants germline mutation (very rare) somatic mutation
33 Should I look for germline origin of a variant? Clinical suspicious? Variant fraction of 50% (or 100%)? Variant with high prevalence in patients with Li Fraumeni (like) syndrome.
34 Should I look for germline origin of a variant? Clinical suspicious? Variant fraction of 50% (or 100%)? Variant with high prevalence in patients with Li Fraumeni (like) syndrome?
35 Should I look for germline origin of a variant? Clinical suspicious? Variant fraction of 50% (or 100%)? Variant with high prevalence in patients with Li Fraumeni (like) syndrome?
36 Should I look for germline origin of a variant? Clinical suspicious? Variant fraction of 50% (or 100%)? Variant with high prevalence in patients with Li Fraumeni (like) syndrome?
37 % of Respondents Should I look for germline origin of a variant? Clinical suspicious? Variant fraction of 50% (or 100%)? Variant with high prevalence in patients with Li Fraumeni (like) syndrome Do you verify somatic origin of detected variants? 37,29 25,42 20,34 Never In suspicious Cases Always when possible Always I am not sure ,08 11,86
38 Main aspect: Analysis Report
39 Reporting of TP53 variants - Requirements Lab name / Contact details Lab ID Responsible Person
40 Reporting of TP53 variants - Requirements Lab name / Contact details Date of sample acquisition Patient Identifier Sample ID Responsible Person
41 Reporting of TP53 variants - Requirements Lab name / Contact details Analysis details Date of sample acquisition Patient Identifier Type of analysis Type of material and technique (Sensitivity / Specificity) Exons covered & Reference Seq Responsible Person
42 Reporting of TP53 variants - Requirements Lab name / Contact details Result Date of sample acquisition Patient Identifier Type of analysis Type of material and technique (Sensitivity / Specificity) Exons covered & Reference Seq Result Interpretation Reference Responsible Person
43 321t5:c.128G>A Reporting of TP53 variants - Requirements Result 1) Mutated or Unmutated TP53 status 2) Type of mutation (missense, nonsense) 3) Use HGVS to describe mutations chr17.hg19:g c>t or alternatively NG_ :g.17463G>A c.524g>a (NM_ ) p.r175h
44 Reporting of TP53 variants - Requirements Result 1) Mutated or Unmutated TP53 status 2) Type of mutation (missense, nonsense) 3) Use HGVS to describe mutations chr17.hg19:g c>t or alternatively NG_ :g.17463G>A c.524g>a (NM_ ) p.r175h Interpretation summary of the finding in the context of the current state of knowledge (reference)
45 Reporting of TP53 variants Optional results Variant fraction Allelic fraction or cancer cell fraction? Consider tumor content For NGS directly from variant calling > PCR duplicates can give wrong results (>UMIs) > chromosomal Aberrations give wrong results For Sanger only estimation possible Both: Understimation of subclonal TP53 mutations
46 % of Respondents % of Respondents Reporting of TP53 variants Optional results When using NGS, what is the VAF you currently set as the cut-off for reporting in the clinic? 0 9,8 15,69 23,53 3,92 29,41 17,65 <1% 1% 5% 10% We report all found variants irrespective of the VAF I am not sure Other VAF Do you report over-time changes in VAF when the patient is analysed repeatedly? 50,85 13,56 35,59 Response Yes No I am not sure
47 Reporting of TP53 variants Optional results No clinical impact no clinical need for reporting SNP Causing confusion: ( This SNP is likely benign, possible clinical significance affecting drug response. ) Actually providing germline data (Patient identification) => Not recommended
48 % of Respondents Reporting of TP53 variants Optional results Do you report known polymorphisms and benign variants to clinicians? SNP 70 66,1 No clinical impact no clinical need for reporting 60 Causing confusion: ( This SNP is likely benign, possible clinical 50 significance affecting drug response. ) 40 Actually providing germline data (Patient identification) 30 => Not recommended ,95 6,78 5,08 No Yes, only benign variants other than described polymorphisms Yes, only known polymorphisms Yes, Both I am not sure 5,08
49 Reporting of TP53 variants - Requirements Lab name / Contact details Result Date of sample acquisition Patient Identifier Type of analysis Type of material and technique (Sensitivity / Specificity) Exons covered & Reference Seq Result Interpretation Reference Responsible Person
50 Acknowledgements Ulm Hartmut Döhner Stephan Stilgenbauer Eva Moll Melanie Flauger Antonia Feist Sabrina Kless Christina Galler ERIC Office Natalie Sorolla Sonia Amaral Martin Fox ERIC Jitka Malcikova Sarka Pospisilova Davide Rossi Paolo Ghia Kostas Stamatopoulos
BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING
Technical aspects of TP53 mutation analysis: BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic TP53 gene in CLL: KEEP
More informationTP53 ABERRATIONS Methodical considerations
TP53 ABERRATIONS Methodical considerations Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic Belgrade March 16-17, 2018 TP53 gene in CLL: modes of inactivation mutation(s)
More informationTP53 mutational profile in CLL : A retrospective study of the FILO group.
TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :
More informationTHE UMD TP53 MUTATION DATABASE UPDATES AND BENEFITS. Pr. Thierry Soussi
THE UMD TP53 MUTATION DATABASE UPDATES AND BENEFITS Pr. Thierry Soussi thierry.soussi@ki.se thierry.soussi@upmc.fr TP53: 33 YEARS AND COUNTING STRUCTURE FUNCTION RELATIONSHIP OF WILD AND MUTANT TP53 1984
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationERIC TP53 Network activities and outcomes. Sarka Pospisilova
ERIC TP53 Network activities and outcomes Sarka Pospisilova ERIC TP53 NETWORK 11 Training Centres 3 Certifying Centres Uppsala/Stockholm Belfast Copenhagen Amsterdam Paris Ulm Novara Brno Bellinzona Salamanca
More informationVariant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18
Variant interpretation exercise ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Format of exercise Compile a list of tricky variants across solid cancer and haematological malignancy.
More informationUpdate on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4
Update on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4 Sarka Pospisilova Jitka Malcikova CEITEC, Masaryk University and University Hospital Brno, Czech Republic
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationConcurrent Practical Session ACMG Classification
Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More information6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels
Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA
More informationIntroduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016
Introduction to genetic variation He Zhang Bioinformatics Core Facility 6/22/2016 Outline Basic concepts of genetic variation Genetic variation in human populations Variation and genetic disorders Databases
More informationNGS panels in clinical diagnostics: Utrecht experience. Van Gijn ME PhD Genome Diagnostics UMCUtrecht
NGS panels in clinical diagnostics: Utrecht experience Van Gijn ME PhD Genome Diagnostics UMCUtrecht 93 Gene panels UMC Utrecht Cardiovascular disease (CAR) (5 panels) Epilepsy (EPI) (11 panels) Hereditary
More informationPALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.
Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12
More informationFunctional analysis of DNA variants
Functional analysis of DNA variants GS011143, Introduction to Bioinformatics The University of Texas GSBS program, Fall 2012 Ken Chen, Ph.D. Department of Bioinformatics and Computational Biology UT MD
More informationMutationTaster & RegulationSpotter
MutationTaster & RegulationSpotter Pathogenicity Prediction of Sequence Variants: Past, Present and Future Dr. rer. nat. Jana Marie Schwarz Klinik für Pädiatrie m. S. Neurologie Exzellenzcluster NeuroCure
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationCHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE
CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE is_clinical dbsnp MITO GENE chr1 13273 G C heterozygous - - -. - DDX11L1 chr1 949654 A G Homozygous 52 - - rs8997 - ISG15 chr1 1021346 A G heterozygous
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationVariant Classification. Author: Mike Thiesen, Golden Helix, Inc.
Variant Classification Author: Mike Thiesen, Golden Helix, Inc. Overview Sequencing pipelines are able to identify rare variants not found in catalogs such as dbsnp. As a result, variants in these datasets
More informationMutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
More informationShashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics
Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Director of Cytogenomics and Molecular Pathology Evidence-based
More informationCorrespondence to Nature Genetics: Exploring pediatric cancer mutation information using ProteinPaint
SUPPLEMENTARY INFORMATION FOR Correspondence to Nature Genetics: Exploring pediatric cancer mutation information using ProteinPaint Xin Zhou 1, Michael Edmonson 1, Mark R. Wilkinson 1, Aman Patel 1, Gang
More informationBio 111 Study Guide Chapter 17 From Gene to Protein
Bio 111 Study Guide Chapter 17 From Gene to Protein BEFORE CLASS: Reading: Read the introduction on p. 333, skip the beginning of Concept 17.1 from p. 334 to the bottom of the first column on p. 336, and
More informationBioinformatics Laboratory Exercise
Bioinformatics Laboratory Exercise Biology is in the midst of the genomics revolution, the application of robotic technology to generate huge amounts of molecular biology data. Genomics has led to an explosion
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationGolden Helix s End-to-End Solution for Clinical Labs
Golden Helix s End-to-End Solution for Clinical Labs Steven Hystad - Field Application Scientist Nathan Fortier Senior Software Engineer 20 most promising Biotech Technology Providers Top 10 Analytics
More informationGenetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT
GBinsight Sample Name: GB4411 Race: Gender: Female Reason for Testing: Type 2 diabetes, early onset MRN: 0123456789 Specimen: Saliva Received: 07/26/2016 Test ID: 113-1487118782-4 Test: Type 2 Diabetes
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationMRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.
SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationUnderstanding The Genetics of Diamond Blackfan Anemia
Understanding The Genetics of Diamond Blackfan Anemia Jason Farrar, MD jefarrar@ About Me Assistant Professor of Pediatrics at University of Arkansas for Medical Sciences & Arkansas Children s Hospital
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationAuthor's response to reviews
Author's response to reviews Title: EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis Authors: Antti Kokko (antti.kokko@helsinki.fi) Paivi Laiho (paivi.laiho@helsinki.fi)
More informationTherapy-related acute myeloid leukemia with germline TP53 mutation (Li-Fraumeni syndrome) SH Chelsey Deel MD Teresa Scordino MD
Therapy-related acute myeloid leukemia with germline TP53 mutation (Li-Fraumeni syndrome) SH2017-167 Chelsey Deel MD Teresa Scordino MD Clinical History HPI: 44 year old Caucasian female referred for evaluation
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationResearch Strategy: 1. Background and Significance
Research Strategy: 1. Background and Significance 1.1. Heterogeneity is a common feature of cancer. A better understanding of this heterogeneity may present therapeutic opportunities: Intratumor heterogeneity
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationThe Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
More informationSupplementary Figure 1. Estimation of tumour content
Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent
More informationIntroduction. Introduction
Introduction We are leveraging genome sequencing data from The Cancer Genome Atlas (TCGA) to more accurately define mutated and stable genes and dysregulated metabolic pathways in solid tumors. These efforts
More informationNEXT GENERATION SEQUENCING. R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca
NEXT GENERATION SEQUENCING R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca SANGER SEQUENCING 5 3 3 5 + Capillary Electrophoresis DNA NEXT GENERATION SEQUENCING SOLEXA-ILLUMINA
More informationIdentifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine
Raphael et al. Genome Medicine 2014, 6:5 REVIEW Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine Benjamin J Raphael 1,2*, Jason R Dobson 1,2,3,
More informationBWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space
Whole genome sequencing Whole exome sequencing BWA alignment to reference transcriptome and genome Convert transcriptome mappings back to genome space genomes Filter on MQ, distance, Cigar string Annotate
More informationAnalysis with SureCall 2.1
Analysis with SureCall 2.1 Danielle Fletcher Field Application Scientist July 2014 1 Stages of NGS Analysis Primary analysis, base calling Control Software FASTQ file reads + quality 2 Stages of NGS Analysis
More informationSupplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the
More informationWelcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm
Welcome to the Genetic Code: An Overview of Basic Genetics October 24, 2016 12:00pm 3:00pm Course Schedule 12:00 pm 2:00 pm Principles of Mendelian Genetics Introduction to Genetics of Complex Disease
More informationVariant Classification: ACMG recommendations. Andreas Laner MGZ München
Variant Classification: ACMG recommendations Andreas Laner MGZ München laner@mgz-muenchen.de Overview Introduction ACMG-AMP Classification System Evaluation of inter-laboratory concordance in variant classification
More informationSupplemental Information For: The genetics of splicing in neuroblastoma
Supplemental Information For: The genetics of splicing in neuroblastoma Justin Chen, Christopher S. Hackett, Shile Zhang, Young K. Song, Robert J.A. Bell, Annette M. Molinaro, David A. Quigley, Allan Balmain,
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationCardiology Genetics Report Long QT Syndrome (LQTS) Panel
Patient Name: Test(s) Requested: The ordered test and the genes analyzed are Genes Evaluated (Disease): Result: Only mutations detected appear here KCNQ1 (LQT1 and Jervell and LangeNielsen syndrome), KCNH2
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationWhat we know about Li-Fraumeni syndrome
What we know about Li-Fraumeni syndrome Dr Helen Hanson Consultant in Cancer Genetics St Georges Hospital, South-West Thames Regional Genetics Service History of LFS 1969 Li and Fraumeni describe four
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationSupplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established
Supplementary Figure 1: Classification scheme for nonsynonymous and nonsense germline MC1R variants. The common variants with previously established classifications 1 3 are shown. The effect of novel missense
More informationSUPPLEMENTARY INFORMATION. Intron retention is a widespread mechanism of tumor suppressor inactivation.
SUPPLEMENTARY INFORMATION Intron retention is a widespread mechanism of tumor suppressor inactivation. Hyunchul Jung 1,2,3, Donghoon Lee 1,4, Jongkeun Lee 1,5, Donghyun Park 2,6, Yeon Jeong Kim 2,6, Woong-Yang
More informationVariant Classification: ACMG recommendations. Andreas Laner MGZ München
Variant Classification: ACMG recommendations Andreas Laner MGZ München laner@mgz-muenchen.de OVERVIEW Introduction ACMG-AMP Classification System Evaluation of inter-laboratory concordance in variant classification
More informationMRC-Holland MLPA. Description version 29; 31 July 2015
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082
More informationBRCA1 and BRCA2 germline muta-ons in Moroccan breast/ovarian cancer families
BRCA1 and BRCA2 germline muta-ons in Moroccan breast/ovarian cancer families A Tazzite a, H Jouhadi b, A Benider b, K Hamzi a and S Nadifi a a Genetics and Molecular Pathology Laboratory, Medical School
More informationSupplementary Text. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Supplementary Text Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry Takaya Moriyama a, Yung-Li Yang b, Rina Nishii a, c, Hany Ariffin
More informationISOWN: accurate somatic mutation identification in the absence of normal tissue controls
Kalatskaya et al. Genome Medicine (2017) 9:59 DOI 10.1186/s13073-017-0446-9 SOFTWARE ISOWN: accurate somatic mutation identification in the absence of normal tissue controls Irina Kalatskaya 1*, Quang
More informationUsing SuSPect to Predict the Phenotypic Effects of Missense Variants. Chris Yates UCL Cancer Institute
Using SuSPect to Predict the Phenotypic Effects of Missense Variants Chris Yates UCL Cancer Institute c.yates@ucl.ac.uk Outline SAVs and Disease Development of SuSPect Features included Feature selection
More informationNo mutations were identified.
Hereditary High Cholesterol Test ORDERING PHYSICIAN PRIMARY CONTACT SPECIMEN Report date: Aug 1, 2017 Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA Kelly Peters Sample Medical Group 123
More informationEpigenetic programming in chronic lymphocytic leukemia
Epigenetic programming in chronic lymphocytic leukemia Christopher Oakes 10 th Canadian CLL Research Meeting September 18-19 th, 2014 Epigenetics and DNA methylation programming in normal and tumor cells:
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationMRC-Holland MLPA. Description version 29;
SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,
More informationSupplementary Methods
Supplementary Methods Short Read Preprocessing Reads are preprocessed differently according to how they will be used: detection of the variant in the tumor, discovery of an artifact in the normal or for
More information6.3 DNA Mutations. SBI4U Ms. Ho-Lau
6.3 DNA Mutations SBI4U Ms. Ho-Lau DNA Mutations Gene expression can be affected by errors that occur during DNA replication. Some errors are repaired, but others can become mutations (changes in the nucleotide
More informationIdentification of genomic alterations in cervical cancer biopsies by exome sequencing
Chapter- 4 Identification of genomic alterations in cervical cancer biopsies by exome sequencing 105 4.1 INTRODUCTION Athough HPV has been identified as the prime etiological factor for cervical cancer,
More informationIdentifying Mutations Responsible for Rare Disorders Using New Technologies
Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance
More informationERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 ERIC recommendations for TP53 mutation analysis in chronic lymphocytic
More informationAuthor Version: Published ahead of online first
AUTHOR VERSION Author Version: Published ahead of online first ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia update on methodological approaches and results interpretation
More informationBeta Thalassemia Case Study Introduction to Bioinformatics
Beta Thalassemia Case Study Sami Khuri Department of Computer Science San José State University San José, California, USA sami.khuri@sjsu.edu www.cs.sjsu.edu/faculty/khuri Outline v Hemoglobin v Alpha
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationVariant Annotation and Functional Prediction
Variant Annotation and Functional Prediction Copyrighted 2018 Isabelle Schrauwen and Suzanne M. Leal This exercise touches on several functionalities of the program ANNOVAR to annotate and interpret candidate
More informationMolecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations
Korean J Lab Med 2010;30:190-4 DOI 10.3343/kjlm.2010.30.2.190 Original Article Diagnostic Genetics Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report
More informationGenética del Feocromocitoma/Paraganglioma.
Genética del Feocromocitoma/Paraganglioma. Mercedes Robledo, PhD Head of the Hereditary Endocrine Cancer Group Human Cancer Genetics Programme CNIO, Madrid, Spain. mrobledo@cnio.es High susceptibility
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationCHAPTER IV RESULTS Microcephaly General description
47 CHAPTER IV RESULTS 4.1. Microcephaly 4.1.1. General description This study found that from a previous study of 527 individuals with MR, 48 (23 female and 25 male) unrelated individuals were identified
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationComprehensive genomic profiling for various solid tumors
Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationIgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece
IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece Troubleshooting Standardization Standardization and
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationSection Chapter 14. Go to Section:
Section 12-3 Chapter 14 Go to Section: Content Objectives Write these Down! I will be able to identify: The origin of genetic differences among organisms. The possible kinds of different mutations. The
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Systematic investigation of cancer-associated somatic point mutations in SNP databases HyunChul Jung 1,2, Thomas Bleazard 3, Jongkeun Lee 1 and Dongwan Hong 1 1. Cancer Genomics
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More information